SARS-CoV-2 Reagents and Services Related Citations

The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in unprecedented crisis to the global health. The SARS-CoV-2 has spread into over 188 countries and sickened over 56.9M people worldwide. A timely response to virus outbreaks in terms of the developments of both diagnostic tools and therapeutics is essential to combat such invisible enemies. To support these studies, Sino Biological has developed a comprehensive panel of antibodies and antigens for SARS-CoV-2. Sino Biological also specializes in recombinant antigen and antibody production. The ProVirTM collection is the world largest viral antigen bank, including over 800 proteins from 350 viral strains.

Up to 15th October, there are 284 publications that have cited SARS-CoV-2 reagents or services providing by Sino Biological Inc.

1. Cao, L,et al.De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.Science (New York, N.Y.).2020

2. Hansen, J,et al.Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.Science (New York, N.Y.).2020

3. Chandrashekar, A,et al.SARS-CoV-2 infection protects against rechallenge in rhesus macaques.Science (New York, N.Y.).2020

4. Chan, KK,et al.Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Science.2020

5. Gu, H,et al.Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.Science.2020

6. Deng, W,et al.Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.Science.2020

7. Brouwer, PJM,et al.Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.Science.2020

8. Renhong Yan,et al.Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.Science.2020

9. Lamers, MM,et al.SARS-CoV-2 productively infects human gut enterocytes.Science.2020

10. Rockx, B,et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.Science.2020

11. Yu, J,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science.2020

12. Xiangyang Chi,et al.A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.Science.2020

13. Zhe Lv,et al.Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent theraprutic antibody.Science.2020

14. Bin Ju,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection.Nature.2020

15. Linlin Bao,et al.The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice.Nature.2020

16. Dora Pinto,et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature.2020

17. Bojkova, D,et al.Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature.2020

18. Liu, L,et al.Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike.Nature.2020

19. Ke, Z,et al.Structures and distributions of SARS-CoV-2 spike proteins on intact virions.Nature.2020

20. Meckiff, B,et al.Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19.Cell.2020

21. Piccoli, L,et al.Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.Cell.2020

22. Yurkovetskiy, L,et al.Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.Cell.2020

23. Du, S,et al.Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.Cell.2020

24. Li, W,et al.High potency of a bivalent human VH domain in SARS-CoV-2 animal models.Cell.2020

25. Cao, Y,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\' B cells.Cell.2020

26. Wrapp, Daniel,et al.Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.Cell.2020

27. Sun, J,et al.Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.Cell.2020

28. Wang, H,et al.Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.Cell.2020

29. Dai, L,et al.A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.2020

30. Li, Q,et al.The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.Cell.2020

31. Zhang, N,et al.A thermostable mRNA vaccine against COVID-19.Cell.2020

32. Chi, X,et al.Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.Nature communications.2020

33. Rudberg, AS,et al.SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.Nature Communications .2020

34. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.Nature Communications .2020

35. Jiang, HW,et al.SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.Nature Communications .2020

36. Wang, C,et al.A human monoclonal antibody blocking SARS-CoV-2 infection.Nature Communications .2020

37. Ou, X,et al.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Nature Communications .2020

38. Deng, W,et al.Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.Nature Communications .2020

39. Smith, TRF,et al.Immunogenicity of a DNA vaccine candidate for COVID-19.Nature Communications .2020

40. Noy-Porat, T,et al.A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.Nature Communications .2020

41. Zhao, H,et al.A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.Nature Communications .2020

42. Feng, L,et al.An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.Nature Communications .2020

43. Ripperger, T,et al.Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity..Immunity.2020

44. Ni, L,et al.Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.Immunity.2020

45. Laczkó, D,et al.A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice.Immunity.2020

46. Tostanoski, LH,et al.Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.Nature Medicine.2020

47. Long, QX,et al.Antibody responses to SARS-CoV-2 in patients with COVID-19.Nature Medicine.2020

48. Amanat F,et al.A serological assay to detect SARS-CoV-2 seroconversion in humans.Nature Medicine.2020

49. McCallum, M,et al.Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.Nat. Struct. Mol. Biol.2020

50. Wu, Y,et al.Identification of Human Single-Domain Antibodies against SARS-CoV-2.Cell Host Microbe.2020

51. Dieterle, M,et al.A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition.Cell Host & Microbe.2020

52. Stanifer, ML,et al.Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.Cell Rep.2020

53. Zhang, H,et al.Activation of Peroxiredoxin 1 by Fluvastatin Effectively Protects from Inflammation and SARS-CoV-2.Cell Metabolism.2020

54. Huibin LvCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Reports.2020

55. Yi, C,et al.Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell. Mol. Immunol.2020

56. Schurink, B,et al.Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.The Lancet Microbe.2020

57. Matschke, J,et al.Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.Lancet Neurol.2020

58. Xiao, F,et al.Evidence for gastrointestinal infection of SARS-CoV-2.Gastroenterology.2020

59. Seo, G,et al.Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.ACS Nano.2020

60. Su, H,et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int..2020

61. Ye, L,et al.Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.Cellular & Molecular Immunology.2020

62. Bing ZhaoRecapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.Protein&Cell.2020

63. Chia, WN,et al.Serological differentiation between COVID-19 and SARS infections.Emerg Microbes Infect.2020

64. Sun B,et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.Emerg Microbes Infect..2020

65. Shan-Meng Lin,et al.Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.J. Med. Chem.2020

66. Liu, X,et al.Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.Acta Pharm Sin B.2020

67. Liu, X,et al.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B.2020

68. Okba, NMA,et al.Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.Emerging Infect. Dis.2020

69. Sangeun Jeon,et al.Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.Antimicrob Agents Chemother.2020

70. Zeng, W,et al.Biochemical characterization of SARS-CoV-2 nucleocapsid protein.Biochemical and Biophysical Research Communications.2020

71. Fujita, R,et al.Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system.Biochemical and Biophysical Research Communications.2020

72. Chen, Z,et al.A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein.Virol Sin.2020

73. Huang, S,et al.Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.Biomedical Journal.2020

74. Musarrat, F,et al.The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.J Med Virol.2020

75. Pu, T,et al.Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.J. Med. Virol.2020

76. Carnevale, S,et al.Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea.J. Med. Virol.2020

77. Zeng, X,et al.Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.Antibody Therapeutics.2020

78. Sobrevilla, JMV;¿ Por qué los pacientes con diabetes o hipertensión son más susceptibles a tener COVID-19?.Conference.2020

79. Harcourt, Jennifer,et al.Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States.Emerging Infectious Diseases.2020

80. Feng, Siqin,et al.Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases.2020

81. Zeng, X,et al.Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens.JCI Insight.2020

82. Larsen, CP,et al.Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19).Kidney Int Rep.2020

83. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection.Research Square.2020

84. Kanjanasirirat, P,et al.High-Content Screening of Thai Medicinal Plants Reveals Boesenbergia rotunda Extract and its Component Panduratin A as Anti-SARS-CoV-2 Agents.Research Square.2020

85. Yang, J,et al.Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.Research Square.2020

86. Bdr-Eldeen, O;What we should understand about SARS-COV-2 GENOME..researchgate.net.2020

87. Ravichandran, Supriya,et al.Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.Science Translational Medicine.2020

88. Zhou, R,et al.Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.SSRN Journal.2020

89. Cheng, Y,et al.Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.SSRN Journal.2020

90. 彭浩然,et al.上海 2 株严重急性呼吸综合征冠状病毒 2 的分离与鉴定.第二军医大学学报.2020

91. Yu, P,et al.Age-related rhesus macaque models of COVID-19.Anim Models Exp Med.2020

92. Turista, D,et al.Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia.J. Pure Appl. Microbiol.2020

93. Belete, T;A review on Promising vaccine development progress for COVID-19 disease.Vacunas.2020

94. Gan, JH;Discovery of small molecule therapeutics for the Middle Eastern respiratory syndrome-coronavirus (MERS-CoV).Thesis.2020

95. Wang, C,et al.Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.EBioMedicine.2020

96. Lei, H,et al.SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients.Influenza Other Respir Viruses.2020

97. Hernandez, J,et al.Dodging COVID-19 infection: Low expression and localization of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in Mesenchymal Stem Cells derived from human umbilical cord (hUC-MSCs)..Research Square.2020

98. Wu, S,et al.A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge.Research Square.2020

99. Liu, L;Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: A case report.Research Square.2020

100. Ren, L,et al.The Kinetics of Humoral Response and its Relationship with the Disease Severity in COVID-19.Research Square.2020

101. Tang, X,et al.Spike protein up-regulates inflammatory axis of both thromboinflammation and leukotriene in severe COVID-19.Research Square.2020

102. Zhang, X,et al.Engineering mesenchymal stem cells with neutralizing and anti- inflammation dual-capability against SARS-CoV-2 infection.Research Square.2020

103. Ahmadivand, A,et al.Femtomolar-level detection of SARS-CoV-2 spike proteins using toroidal plasmonic metasensors.arXiv preprint.2020

104. 彭浩然,et al.严重急性呼吸综合征冠状病毒 2 假病毒的制备及验证.第二军医大学 .2020

105. Ratajczak, MZ,et al.SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45- Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome.Stem Cell Rev Rep.2020

106. Hu, J,et al.Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.Genes & Diseases.2020

107. Xu, L,et al.COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2.Zool Res.2020

108. Wang, Y,et al.SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.J. Med. Virol.2020

109. Chiuppesi, F,et al.Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.Res Sq.2020

110. Kumar, D,et al.Prospective Observational Study of Screening Asymptomatic Healthcare Workers for SARS-CoV-2 at a Canadian Tertiary Care Center.medRxiv.2020

111. Cate, D,et al.Antibody Screening Results for Anti-Nucleocapsid Antibodies Towards the Development of a SARS-CoV-2 Nucleocapsid Protein Antigen Detecting Lateral Flow Assay.ChemRxiv.2020

112. Feng, Z,et al.Detection of the SARS-CoV-2 Nucleocaspid Protein (NP) Using Immunohistochemistry.BIO-PROTOCOL.2020

113. Tosif, S,et al.Immune responses to SARS-CoV-2 in children of parents with symptomatic COVID-19.Research Square.2020

114. Brocato, RL,et al.Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters.Research Square.2020

115. Gorshkov, K,et al.Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis.ACS Nano.2020

116. Tan, X,et al.Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation.Biosensors and Bioelectronics.2020

117. Al-Dalahmah, O,et al.Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage.Acta Neuropathol Commun.2020

118. McAndrews, KM,et al.Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity.JCI Insight.2020

119. van Tol, S,et al.Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex Approach.Emerg Microbes Infect.2020

120. Li, Y,et al.SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig.J. Virol..2020

121. Wang, N,et al.Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.Phytomedicine.2020

122. Saha, R,et al.Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.Front. Pharmacol..2020

123. Mirzaei, R,et al.Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.Int. Immunopharmacol..2020

124. Xiao, C,et al.Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2.Influenza Other Respir Viruses.2020

125. Wheeler, SE,et al.Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients.Clin. Biochem.2020

126. Li, N,et al.Molecular diagnosis of COVID‑19: Current situation and trend in China (Review).Exp Ther Med.2020

127. Yang, R,et al.Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro.Biosaf Health.2020

128. Liu, L,et al.Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19.ACS Appl. Bio Mater..2020

129. Wang, G,et al.Degradation of SARS-CoV-2 Receptor ACE2 by Tobacco Carcinogens.SSRN Journal.2020

130. Liu, Z,et al.The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection.Research Square.2020

131. Azad, T,et al.Nanoluciferase complementation-based biosensor reveals the importance of N- linked glycosylation of SARS-CoV-2 Spike for viral entry.Research Square.2020

132. Grant, BD,et al.A SARS-CoV-2 Coronavirus Nucleocapsid Protein Antigen-Detecting Lateral Flow Assay.ChemRxiv.2020

133. Renn, A,et al.Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2.Trends in Pharmacological Sciences.2020

134. Ko, M,et al.Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.J. Med. Virol.2020

135. Hsu, A,et al.Placental SARS-CoV-2 in a Pregnant Woman with Mild COVID-19 Disease.J. Med. Virol.2020

136. Ko, CJ,et al.Perniosis during the COVID-19 pandemic: Negative Anti-SARS-CoV-2 Immunohistochemistry in Six Patients and Comparison to Perniosis Before the Emergence of SARS-CoV-2.J. Cutan. Pathol..2020

137. Schasfoort, R,et al.Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.Research Square.2020

138. pandolfi, l,et al.Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.Research Square.2020

139. Gupta, Y,et al.Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays.Research Square.2020

140. Zeng, C,et al.Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.Adv. Mater. Weinheim.2020

141. Yu, J,et al.Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.Blood.2020

142. Schäfer, R,et al.Human Mesenchymal Stromal Cells are resistant to SARS-CoV-2 Infection under Steady State, Inflammatory Conditions and in the Presence of SARS-CoV-2 infected Cells.Stem Cell Reports.2020

143. Xiong, HL,et al.Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.Emerg Microbes Infect.2020

144. Zhang, Q,et al.A serological survey of SARS-CoV-2 in cat in Wuhan.Emerg Microbes Infect.2020

145. Gianotti, R,et al.Similarities in Cutaneous Histopathological Patterns between COVID-19-positive and COVID-19 High-risk Patients with Skin Dermatosis.Acta Derm. Venereol..2020

146. Azad, T,et al.Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.Membranes (Basel).2020

147. McGregor, R,et al.Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand.PeerJ.2020

148. Diorio, C,et al.Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.Pediatr Blood Cancer.2020

149. Demers-Mathieu, V,et al.Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk.J Perinatol.2020

150. Lee, SY,et al.A Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2.Research Square.2020

151. Cantera, J,et al.Screening Antibodies Raised Against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays.ChemRxiv.2020

152. Norman, M,et al.Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19.Nature biomedical engineering.2020

153. Pierce, CA,et al.Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.Science translational medicine.2020

154. Segalés, J,et al.Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain.Proceedings of the National Academy of Sciences of the United States of America.2020

155. Cazares, LH,et al.Development of a parallel reaction monitoring (PRM) mass spec-trometry-assay for the detection of SARS-CoV-2 spike glycoprotein and nucleoprotein.Anal. Chem..2020

156. Lee, S,et al.Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells.Emerg Microbes Infect.2020

157. Jin, W,et al.The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.International journal of biological macromolecules.2020

158. Rayner, JO,et al.AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.Biochemical pharmacology.2020

159. Yu, S,et al.Glycyrrhizic Acid Exerts Inhibitory Activity against the Spike Protein of SARS-CoV-2.Phytomedicine.2020

160. Omotuyi, IO,et al.Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.Phytother Res.2020

161. Liu, X,et al.Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.Vaccine.2020

162. Ko, CJ,et al.Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein.Journal of cutaneous pathology.2020

163. Oishee, M,et al.COVID-19 diagnostics: Current and Prospective Tools.Journal of Translational Autoimmunity.2020

164. Dong, J,et al.Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.Research Square.2020

165. Tao, W,et al.Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18.Medicine in Microecology.2020

166. Jacob, F,et al.Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium.Cell Stem Cell.2020

167. Liu, Q,et al.Pathological changes in the lungs and lymphatic organs of twelve COVID-19 autopsy cases.National Science Review.2020

168. Zeng, H,et al.The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.Signal Transduct Target Ther.2020

169. Lee, J,et al.A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).Biosensors and Bioelectronics.2020

170. Cady, N,et al.Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform.Biosensors and Bioelectronics.2020

171. Rao, L,et al.Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines.Proc Natl Acad Sci U S A.2020

172. Bosco-Lauth, AM,et al.Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats.Proc Natl Acad Sci U S A.2020

173. Chen, X,et al.Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.Acta Pharmaceutica Sinica B.2020

174. Li, H,et al.Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.Emerg Microbes Infect.2020

175. Luetkens, T,et al.Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.Blood Adv.2020

176. Hopfer, H,et al.Hunting coronavirus by transmission electron microscopy - a guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues.Histopathology.2020

177. Alandijany, TA,et al.Development and Optimization of In-house ELISA for Detection of Human IgG Antibody to SARS-CoV-2 Full Length Spike Protein.Pathogens.2020

178. Barisione, E,et al.Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems.Virchows Arch.2020

179. Huang, PH,et al.Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.Hum Vaccin Immunother.2020

180. Torrente-Rodríguez, RM,et al.SARS-CoV-2 RapidPlex: A Graphene-based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring.Matter.2020

181. Rosenke, K;Hansen, F,et al.Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.Research Square.2020

182. Bullen, CK,et al.Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2.ALTEX.2020

183. Kim, SY,et al.Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.Antiviral Res.2020

184. Takeda, Y,et al.Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.Viruses.2020

185. Yee, JL,et al.SARS-CoV-2 surveillance for a non-human primate breeding research facility.J. Med. Primatol..2020

186. Li, Z,et al.Cell-Mimicking Nanodecoys Protect Lung Cells by Neutralization of SARS-CoV-2 Spike Proteins.Research Square.2020

187. Wang, Z,et al.COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium Injury.Am. J. Respir. Crit. Care Med..2020

188. Tzankov, A,et al.Unlocking the lockdown of science and demystifying COVID-19: how autopsies contribute to our understanding of a deadly pandemic.Virchows Arch..2020

189. Chen, W,et al.Reducing false negatives in COVID-19 testing by using microneedle-based oropharyngeal swabs.Matter.2020

190. Chandrasekar, SS,et al.A Novel Mucosal Adjuvant System for Immunization against Avian Coronavirus Causing Infectious Bronchitis.J. Virol..2020

191. Prasad, ASV;Local Immunity Concept in the Context of the Novel Corona Viral Infection: A Consideration.bioRxiv.2020

192. Khan, S,et al.Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.BioRxiv.2020

193. Thornburg, N,et al.Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.bioRxiv.2020

194. Chunyun Sun,et al.SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.bioRxiv.2020

195. Milewska, A,et al.HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.bioRxiv.2020

196. Wang, C,et al.Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2.bioRxiv.2020

197. Li, Y,et al.Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1.bioRxiv.2020

198. Xiong, H,et al.Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.bioRxiv.2020

199. Zhang, Q,et al.SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation.bioRxiv.2020

200. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry.bioRxiv.2020

201. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

202. Tan, X,et al.Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.bioRxiv.2020

203. Zhu, Y,et al.Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.bioRxiv.2020

204. Walter, JD,et al.Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.BioRxiv.2020

205. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.BioRxiv.2020

206. Chi X,et al.Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.bioRxiv.2020

207. Kim, SY,et al.Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry.bioRxiv.2020

208. Si L,et al.Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics.bioRxiv.2020

209. Liu L,et al.SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner.bioRxiv.2020

210. Zha L,et al.Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles.bioRxiv.2020

211. Romano, M,et al.An engineered stable mini-protein to plug SARS-Cov2 Spikes.bioRxiv.2020

212. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

213. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.BioRxiv.2020

214. Hedde, PN,et al.A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.bioRxiv.2020

215. Ghazizadeh, Z,et al.Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men.bioRxiv.2020

216. Finch, CL,et al.Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis).bioRxiv.2020

217. Cai, Y,et al.Distinct conformational states of SARS-CoV-2 spike protein.bioRxiv.2020

218. Zang, J,et al.Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.bioRxiv.2020

219. Zost, SJ,et al.Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.bioRxiv.2020

220. Zhang, Y,et al.The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I.bioRxiv.2020

221. Corbett, K,et al.SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.bioRxiv.2020

222. Yang, Y,et al.The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.bioRxiv.2020

223. Daly, J,et al.Neuropilin-1 is a host factor for SARS-CoV-2 infection.bioRxiv.2020

224. Liu, D,et al.Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection.bioRxiv.2020

225. Mesci, P,et al.Sofosbuvir protects human brain organoids against SARS-CoV-2.bioRxiv.2020

226. Bosco-Lauth, A,et al.Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats.bioRxiv.2020

227. Yao, D,et al.Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2.bioRxiv.2020

228. Liu, L,et al.A translatable subunit nanovaccine for COVID-19.Chem Rxiv.2020

229. Song, Y,et al.Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.ChemRxiv.2020

230. Jiang, H,et al.Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv.2020

231. Bo Diao,et al.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv.2020

232. Linlin Bao,et al.Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.medRxiv.2020

233. Linlin Bao,et al.Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.medRxiv.2020

234. Ke Wang,et al.SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.medRxiv.2020

235. Feng, Z,et al.The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes.medRxiv.2020

236. Wei, C,et al.Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies.medRxiv.2020

237. McAndrews, KM,et al.Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19.medRxiv.2020

238. Norman, M,et al.Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients.medRxiv.2020

239. Randad, PR,et al.COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.medRxiv.2020

240. Rosenberg, ES,et al.Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York.medRxiv.2020

241. Phipps, WS,et al.SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity.medRxiv.2020

242. Chakraborty, S,et al.Symptomatic SARS-CoV-2 infections display specific IgG Fc structures.medRxiv.2020

243. Rosendal, E,et al.Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA..medRxiv.2020

244. Mittal, A,et al.COVID-19 Pandemic: Insights into Structure, Function, and hACE2 Receptor Recognition by the SARS-CoV-2.preprints.2020

245. Liu, L,et al.Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike.bioRxiv.2020

246. Beddingfield, B;Iwanaga, N,et al.The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.bioRxiv.2020

247. Salazar, E,et al.Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.bioRxiv.2020

248. Hanson, QM,et al.Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay.bioRxiv.2020

249. Giobbe, G,et al.SARS-CoV-2 infection and replication in human fetal and pediatric gastric organoids.bioRxiv.2020

250. Wang, N,et al.Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus.bioRxiv.2020

251. Liu, J,et al.Engineered human mesenchymal stem cells as new vaccine platform for COVID-19.bioRxiv.2020

252. Hu, J,et al.The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera.bioRxiv.2020

253. Klimstra, W,et al.SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.bioRxiv.2020

254. den Hartog, G,et al.SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence.medRxiv.2020

255. Yahalom-Ronen, Y,et al.A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge.bioRxiv.2020

256. Mulgaonkar, N,et al.Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19.bioRxiv.2020

257. Blair, R;Vaccari, M,et al.ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets.bioRxiv.2020

258. Walker, S,et al.SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients.bioRxiv.2020

259. Stukalov, A,et al.Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV.bioRxiv.2020

260. Liu, T,et al.High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform.bioRxiv.2020

261. Steiner, D,et al.Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients.bioRxiv.2020

262. Ozono, S,et al.Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry.bioRxiv.2020

263. Zhang, J,et al.Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals.medRxiv.2020

264. Zhou, D,et al.Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.bioRxiv.2020

265. Zang, R,et al.Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion.bioRxiv.2020

266. Zhang, G,et al.Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD.bioRxiv.2020

267. Baker, AN,et al.The SARS-COV-2 spike protein binds sialic acids, and enables rapid detection in a lateral flow point of care diagnostic device.PrePrint.2020

268. Rice, A,et al.A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses.bioRxiv.2020

269. Clausen, TM,et al.SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.bioRxiv.2020

270. Li, T,et al.A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.bioRxiv.2020

271. Pomplun, S;Jbara, M,et al.De Novo Discovery of High Affinity Peptide Binders for the SARS-CoV-2 Spike Protein.bioRxiv.2020

272. Chiuppesi, F,et al.Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.bioRxiv.2020

273. Acharya, P,et al.A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies.bioRxiv.2020

274. Zhang, L,et al.The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.bioRxiv.2020

275. Onodi, F,et al.SARS-CoV-2 induces activation and diversification of human plasmacytoid pre-dendritic cells.bioRxiv.2020

276. Du, S,et al.Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.bioRxiv.2020

277. Golden, J,et al.Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease.bioRxiv.2020

278. Langellotto, F,et al.A rapidly adaptable biomaterial vaccine for SARS-CoV-2.bioRxiv.2020

279. Xiao, X,et al.Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2.bioRxiv.2020

280. Xu, C,et al.Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM.bioRxiv.2020

281. Herrmann, A,et al.A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection.bioRxiv.2020

282. Routhu, N,et al.Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response.bioRxiv.2020

283. Ke, Z,et al.Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virions.bioRxiv.2020

284. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins.bioRxiv.2020

Here we list part products cited in those publications.

Cat# Molecule Description Total Cites Citation Number
40591-V08H Spike S1 SARS-CoV-2 Spike S1 Protein, His tag, HPLC-verified 35 6, 15, 33, 38, 39, 50, 59, 61, 64, 87, 91, 108, 110, 115, 116, 152, 169, 180, 186, 192, 194, 196, 200, 202, 205, 213, 232, 233, 236, 238, 254, 260, 278, 281, 284
40589-V08B1 Spike S1+S2 ECD SARS-CoV-2 Spike S1+S2 ECD Protein, His tag 34 23, 25, 39, 73, 87, 96, 98, 105, 109, 110, 115, 183, 185, 192, 200, 204, 205, 206, 209, 213, 221, 229, 236, 239, 251, 258, 261, 264, 269, 273, 273, 276, 282, 284
40592-V05H Spike RBD SARS-CoV-2 Spike RBD Protein, mFc tag, HPLC-verified 19 8, 16, 21, 26, 32, 61, 143, 168, 179, 192, 198, 204, 205, 206, 213, 218, 219, 227, 229
40588-V08B NP-CoV SARS-CoV-2 NP-CoV Protein, His tag 19 64, 83, 96, 109, 110, 111, 118, 119, 155, 180, 185, 187, 192, 205, 213, 239, 241, 254, 278
40592-V08B Spike RBD SARS-CoV-2 Spike RBD Protein, His tag 18 23, 25, 31, 32, 50, 61, 77, 83, 115, 150, 169, 206, 229, 254, 261, 266, 269, 276
40150-V08B1 Spike S1 SARS-CoV Spike S1 Protein, His tag 18 16, 24, 39, 47, 110, 115, 116, 150, 159, 180, 192, 194, 203, 205, 206, 213, 248, 263
40590-V08B Spike S2 SARS-CoV-2 Spike S2 Protein, His tag 12 43, 54, 83, 87, 110, 192, 203, 205, 213, 261, 263, 278
40592-V08H Spike RBD SARS-CoV-2 Spike RBD Protein, His tag 11 87, 108, 109, 110, 116, 118, 211, 237, 239, 256, 260
10108-H08H ACE2 Human ACE2 Protein, His tag, HPLC-verified 10 21, 24, 29, 32, 61, 173, 206, 227, 229, 248
40150-V08B2 Spike RBD SARS-CoV Spike RBD Protein, His tag 9 21, 32, 110, 192, 203, 205, 213, 224, 261
40143-V08B NP-CoV SARS-CoV NP-CoV Protein, His tag 7 47, 51, 68, 110, 192, 205, 213
40591-V02H Spike S1 SARS-CoV-2 Spike S1 Protein, Fc tag 7 95, 157, 192, 201, 205, 212, 213
40600-V08H Spike S1 HCoV-NL63 Spike S1 Protein, His tag 7 48, 110, 147, 153, 192, 205, 213
40601-V08H Spike S1 HCoV-229E Spike S1 Protein, His tag 7 48, 110, 147, 153, 192, 205, 213
40069-V08B Spike S1+S2 ECD MERS-CoV Spike S1+S2 ECD Protein, His tag 7 101, 110, 183, 192, 205, 213, 264
40071-V08B1 Spike RBD MERS-CoV Spike RBD Protein, His tag 7 110, 150, 192, 205, 213, 224, 261
40607-V08B Spike S1+S2 ECD HCoV-OC43 Spike S1+S2 ECD Protein, His tag 7 141, 192, 205, 213, 224, 261, 264
40069-V08H Spike S1 MERS-CoV Spike S1 Protein, His tag 6 59, 110, 192, 194, 205, 213
40605-V08B Spike S1+S2 ECD HCoV-229E Spike S1+S2 ECD Protein, His tag 6 110, 192, 205, 213, 239, 261
40069-V08B1 Spike S1 MERS-CoV Spike S1 Protein, His tag 6 110, 192, 205, 213, 261, 263
40021-V08H Spike S1 HCoV-HKU1 Spike S1 Protein, His tag 5 110, 153, 192, 205, 213
40070-V08B Spike S2 MERS-CoV Spike S2 Protein, His tag 5 110, 192, 205, 213, 263
40602-V08H Spike S1 HCoV-HKU1 Spike S1 Protein, His tag 5 110, 150, 192, 205, 213
40606-V08B Spike S1+S2 ECD HCoV-HKU1 Spike S1+S2 ECD Protein, His tag 5 192, 205, 213, 224, 261
10108-H02H ACE2 Human ACE2 Protein, Fc tag 5 49, 106, 196, 246, 252
10108-H05H ACE2 Human ACE2 Protein, Fc tag 5 24, 77, 161, 169, 258
40591-V08B1 Spike S1 SARS-CoV-2 Spike S1 Protein, His tag 6 24, 110, 236, 261, 263
40150-V31B2 Spike RBD SARS-CoV Spike RBD Protein, rFc Tag 4 192, 194, 205, 213
40068-V08B NP-CoV MERS-CoV NP-CoV Protein, His tag 4 110, 192, 205, 213
40524-V08E PLpro SARS-CoV PLpro Protein, His tag 4 110, 192, 205, 213
40603-V08H HE-CoV HCoV-OC43 HE-CoV Protein, His tag 4 110, 192, 205, 213
10003-V06H1 HA1 H5N1 HA1 Protein, His & Fc Tag 3 192, 205, 213
10003-V06H3 HA1 H5N1 HA1 Protein, His & Fc Tag 3 192, 205, 213
11049-V08B RSV-F RSV RSV-F Protein, His tag 3 192, 205, 213
11070-V08H RSV-G RSV RSV-G Protein, His tag 3 192, 205, 213
11716-V08H HA1 Influenza B HA1 Protein, His tag 3 192, 205, 213
11716-V08H1 HA1 Influenza B HA1 Protein, His tag 3 192, 205, 213
13029-V08H RSV-G RSV RSV-G Protein, His tag 3 192, 205, 213
40035-V08H HA1 H1N1 HA1 Protein, His tag 3 192, 205, 213
40035-V08H1 HA1 H1N1 HA1 Protein, His tag 3 192, 205, 213
40037-V08B RSV-F RSV RSV-F Protein, His tag 3 192, 205, 213
40071-V05B Spike RBD MERS-CoV Spike RBD Protein, mFc Tag 3 192, 205, 213
40071-V31B Spike RBD MERS-CoV Spike RBD Protein, rFc Tag 3 192, 205, 213
40071-V31B1 Spike RBD MERS-CoV Spike RBD Protein, rFc Tag 3 192, 205, 213
40103-V08H HA1 H7N9 HA1 Protein, His tag 3 192, 205, 213
40103-V08H1 HA1 H7N9 HA1 Protein, His tag 3 192, 205, 213
40354-V08B HA1 H3N2 HA1 Protein, His tag 3 192, 205, 213
40354-V08H1 HA1 H3N2 HA1 Protein, His tag 3 192, 205, 213
40458-V08B DcCoV-NP DcCoV DcCoV-NP Protein, His tag 3 192, 205, 213
40498-V08B HA Influenza B HA Protein, His tag 3 192, 205, 213
40498-V08H1 HA Influenza B HA Protein, His tag 3 192, 205, 213
40591-V05H1 Spike S1 SARS-CoV-2 Spike S1 Protein, mFc Tag 3 192, 205, 213
40604-V08B Spike S1+S2 ECD HCoV-NL63 Spike S1+S2 ECD Protein, His tag 3 192, 205, 213
40592-V08B-B Spike RBD SARS-CoV-2 Spike RBD Protein, His tag 3 23, 25, 174
40634-V08B Spike S1+S2 ECD SARS-CoV Spike S1+S2 ECD Protein, His tag 3 183, 261, 264
10108-H08B ACE2 Human ACE2 Protein, His tag, HPLC-verified 2 25, 270
40592-V02H Spike RBD SARS-CoV-2 Spike RBD Protein, Fc tag 2 215, 248
10108-H08H-B ACE2 human ACE2 His tag, Biotinylated 2 161, 282
40592-V08H6 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (F342L),His tag 2 24, 150
40592-V08H7 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (K458R),His tag 2 24, 150
10602-HNAE TNF Human TNF native 1 64
40592-V31H Spike RBD SARS-CoV-2 Spike RBD rFc Tag 1 77
10395-HNAE IL6 human IL6 native 1 91
11055-V08B HA H1N1 HA His tag 1 92
11056-V08B HA H3N2 HA His tag 1 93
11692-V08B HA H1N1 HA His tag 1 94
10690-MNAH IGHG1 mouse IGHG1 Mouse IgG1-Fc Protein (102 Cys/Ser) 1 113
11055-V08H4 HA1 H1N1 HA1 His Tag (A/California/04/2009) 1 115
11675-V08B HA H1N1 HA His Tag 1 116
40589-V27B-B Spike S1+S2 ECD SARS-CoV-2 Spike S1+S2 ECD AVI & His tag, Biotinylated 1 123
40592-V08H1 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (V367F), His tag 1 127
40592-V08H2 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (N354D), His tag 1 128
40592-V08H4 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (A435S), His tag 1 129
40592-V08H5 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (V483A), His tag 1 130
40592-V08H8 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (G476S),His tag 1 131
40592-V08H9 Spike RBD Mutant SARS-CoV-2 Spike RBD Mutant (W436R),His tag 1 132
40593-V07E PLpro SARS-CoV-2 PLpro His tag 1 133
40598-V07E CoV-ME SARS-CoV-2 CoV-ME His tag 1 134
40643-V07E NP-CoV HCoV-OC43 NP-CoV His tag 1 135
90211-C02H ACE2 Rhesus ACE2 Fc Tag 1 136
Cat# Description Antigen Type Total Cites Citation Number
40150-R007 SARS-CoV-2 Spike Antibody Spike Rabbit MAb 14 2, 31, 45, 59, 90, 99, 138, 142, 151, 169, 188, 196, 234, 253
40143-R019 SARS-CoV-2 NP-CoV Antibody NP-CoV Rabbit MAb 11 17, 28, 82, 90, 107, 138, 154, 184, 225, 235, 253
40143-R001 SARS-CoV NP-CoV Antibody NP-CoV Rabbit MAb 10 57, 69, 116, 117, 139, 166, 180, 231, 243, 247
40143-MM05 SARS-CoV Nucleocapsid Antibody Nucleocapsid Mouse MAb 8 19, 52, 180, 181, 249, 275, 277, 283
40143-T62 SARS-CoV NP-CoV Antibody NP-CoV Rabbit PAb 7 10, 27, 57, 58, 60, 67, 109
40592-T62 SARS-CoV-2 Spike RBD Antibody Spike RBD Rabbit PAb 7 11, 118, 223, 237, 239, 265, 282
40150-T62 SARS-CoV Spike S1 Antibody Spike S1 Rabbit PAb 6 37, 81, 162, 244, 272, 277
40150-D001 SARS-CoV Spike Antibody Spike Chimeric MAb 6 31, 45, 116, 151, 208, 273
40150-T52 SARS-CoV Spike Antibody Spike Rabbit PAb 5 31, 75, 79, 193, 194
40150-RP01 SARS-CoV Spike S1 Antibody Spike S1 Rabbit PAb 4 31, 167, 174, 194
40591-MM43 SARS-CoV-2 Spike Antibody Spike Neutralizing Antibody, Mouse Mab 4 115, 116, 140, 151
40592-MM57 SARS-CoV-2 Spike Antibody Spike Neutralizing Antibody, Mouse Mab 4 115, 131, 146, 151
10108-RP01 HIV Gag-p24 Antibody ACE2 Rabbit PAb 3 62, 227, 235
40150-D003 SARS-CoV-2 Spike Antibody Spike Chimeric Mab 3 116, 151, 268
40150-T62-CoV2 SARS Spike Antibody Spike Rabbit PAb 3 28, 109, 136
40588-T62 SARS-CoV-2 NP-CoV Antibody NP-CoV Rabbit PAb 3 118, 120, 187
40150-MM02 SARS-CoV Spike S1 Antibody Spike S1 Mouse MAb 2 37, 281
40590-T62 SARS-CoV-2 Spike S2 Antibody Spike S2 Rabbit PAb 2 184, 265
10108-T56 Human ACE2 Antibody ACE2 Rabbit PAb 1 63
11695-RP01 HIV Gag-p24 Antibody Gag-p24 Rabbit PAb 1 65
11973-MM05T-H M13 Antibody M13 Mouse MAb 1 66
40068-MM10 MERS-CoV NP-CoV Antibody NP-CoV Mouse MAb 1 67
40068-RP02 MERS-CoV NP-CoV Antibody NP-CoV Rabbit PAb 1 68
40070-MM11 MERS-CoV Spike s2 Antibody Spike s2 Mouse MAb 1 69
HG1K Human IgG1, kappa Isotype Control     1 81
SSA009 Goat Anti-Human IgG Secondary Antibody (Biotin)   Secondary Antibody 1 84
11048-MM06 H5N1 HA Antibody HA Mouse MAb 1 114
11684-T62 H1N1 HA Antibody HA Rabbit Pab 1 117
11973-MM05T-H M13 Antibody M13 Mouse MAb 1 118
40143-MM08 SARS-CoV-2 NP-CoV Antibody NP-CoV Mouse Mab 1 119
40143-R004 SARS-CoV-2 NP-CoV Antibody NP-CoV Rabbit Mab 1 120
40150-D002 SARS-CoV-2 Spike Antibody Spike Chimeric Mab 1 121
40150-D006 SARS-CoV-2 Spike Antibody Spike Chimeric Mab 1 122
40590-D001 SARS-CoV-2 Spike S2 Antibody Spike S2 Chimeric Mab 1 124
40592-MP01 SARS-CoV-2 Spike RBD Antibody Spike RBD Mouse Pab 1 126
SSA003 Goat Anti-Rabbit IgG-Fc Secondary Antibody (HRP)   Secondary Antibody 1 137
SSA004 Goat Anti-Rabbit IgG Secondary Antibody (HRP)   Secondary Antibody 1 138
Product Type Cat# Description Total Cites Citation Number
Pseudovirus PSV001 SARS-CoV-2 (2019-nCoV) Spike Pseudovirus 4 121, 129, 224, 250
ELISA KIT40591 SARS-CoV-2 (2019-nCoV) Spike ELISA Kit 3 23, 25, 224
ELISA M293TI SMM 293-TI Expression Medium (Serum free, with Glutamine, complete medium) 3 22, 23, 276
Transfection Reagent STF02 Sinofection Transfection Reagent 2 194, 210
Cell Culture Medium M293TII SMM 293-TII Expression Medium (Serum free, with Glutamine, complete medium) 2 120, 197
Gene VG40150-G-N Human SARS coronavirus (SARS-CoV) Spike glycoprotein Gene ORF cDNA clone expression plasmid (Codon Optimized) 2 194, 256
Gene VG40589-UT SARS-CoV-2 (2019-nCoV) Spike Gene ORF cDNA clone expression plasmid (Codon Optimized) 2 194, 262
Cell Culture Medium MHF1 SIM HF Expression Medium (For Hi5)(Serum free) 2 23, 276
Cell Culture Medium MSF1 SIM SF Expression Medium (For SF9, SF21)(Serum free) 2 23, 276
IP Kit BA10600 Immunoprecipitation Kit -Immunomagnetic Beads Protein A 1 78
Gene CV022 pCMV3-SP-N-Myc Negative Control Vector (N-terminal Myc-tagged) 1 79
Gene HG10108-UT Human ACE2 / Angiotensin-Converting Enzyme 2 Gene ORF cDNA clone expression plasmid 1 80
Gene VG40592-CH SARS-CoV-2 (2019-nCoV) Spike RBD Gene ORF cDNA clone expression plasmid, C-His tag (Codon Optimized) 1 87
CRO Service CRO service CRO service 1 96
Gene HG10108-ACR ACE2 cDNA ORF Clone, Human, C-OFPSpark® tag 1 97
Gene VG40069-G-N MERS-CoV Spike Protein Gene ORF cDNA clone expression plasmid (Codon Optimized) 1 99
Gene VG40588-UT SARS-CoV-2 Nucleocapsid ORF mammalian expression plasmid (Codon Optimized) 1 100
Gene VG40591-CH SARS-CoV-2 Spike S1 Gene ORF cDNA clone expression plasmid, C-His tag (Codon Optimized) 1 101
Gene VG40588-CH SARS-CoV-2 Nucleoprotein Gene ORF cDNA clone expression plasmid, C-His tag (Codon Optimized) 1 139
Gene VG40589-NM SARS-CoV-2 Spike Gene ORF cDNA clone expression plasmid, N-Myc tag (Codon Optimized) 1 140
Recombinant Antibody Production